Effects of cisplatin and pemetrexed on 3D phenotypes of benign mesothelial and malignant pleural mesothelioma cells Source: International Congress 2018 – Clinical management of pleural malignancies, including mesothelioma Year: 2018
Putative cancer stem cells in malignant pleural mesothelioma show resistance to cisplatin and pemetrexed Source: Annual Congress 2010 - Recent developments of molecular pathology and functional genomics in non-neoplastic and neoplastic lung diseases Year: 2010
Systemic treatment of malignant mesothelioma Source: Eur Respir Mon; 2009: 44: 419–434 Year: 2009
Comparison between treatment with IL2, and IL2 in combination with chemotherapy in malignant pleural mesothelioma Source: Annual Congress 2009 - Pleural and mediastinal diseases Year: 2009
Second-line chemotherapy in malignant pleural mesothelioma (MPM) Source: Eur Respir J 2002; 20: Suppl. 38, 273s Year: 2002
Treatment of malignant pleural mesothelioma with caelyx: few responses but good survival Source: Eur Respir J 2004; 24: Suppl. 48, 526s Year: 2004
Satisfractory therapeutic effects of EGFR-TK treatment of a malignant mesothelioma of the pleura: a case report Source: Eur Respir J 2003; 22: Suppl. 45, 30s Year: 2003
Chemotherapy for treatment of malignant pleural mesothelioma Source: Eur Respir J 2004; 24: Suppl. 48, 526s Year: 2004
Polychemotherapy experience in pleural mesothelioma with or without pemetrexed Source: Annual Congress 2009 - Pleural and mediastinal diseases Year: 2009
Evaluation of response to chemotherapy for malignant pleural mesothelioma and suggestion of a new method Source: Eur Respir J 2002; 20: Suppl. 38, 272s Year: 2002
Is there any advantage of chemotherapy on survival of patients with diffuse malignant pleural mesothelioma? Source: Eur Respir J 2003; 22: Suppl. 45, 29s Year: 2003
Systemic therapy 1 in malignant pleural mesothelioma: chemotherapy Source: ERS Online Course 2020: Calendar sheets in malignant pleural diseases Year: 2020
Bevacizumab-targeted therapy for malignant pleural mesothelioma Source: International Congress 2017 – Malignant pleural effusion management in 2017: a review of recent RCTs Year: 2017
Efficacious pleurodesis with OK-432 and doxorubicin against malignant pleural effusions Source: Eur Respir J 2004; 24: 263-266 Year: 2004
Malignant mesothelioma and chemotherapy: efficacy and influence on survival of patients Source: Eur Respir J 2002; 20: Suppl. 38, 272s Year: 2002
The impact of multimodal treatment approaches in patients with malignant pleural mesothelioma Source: Annual Congress 2010 - Diagnostic and therapeutic problems in surgical oncology Year: 2010
Effects of Cisplatin and Pemetrexed on the cell viability and cell adhesion of benign mesothelial and mesothelioma cells. Source: International Congress 2017 – Mesothelioma and malignant pleural disease Year: 2017
Hypotonic carboplatin pleurodesis for malignant pleural effusion of non-small cell lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 273s Year: 2002
In patients with treatment-sensitive cancers, does systemic anti-cancer therapy increase the chance of malignant pleural effusion control? Source: Virtual Congress 2020 – Novel directions in pleural disease: bench to bedside Year: 2020
2-Deoxy-glucose synergizes with Cisplatin and Pemetrexed chemotherapeutics to reduce cell migration of mesothelioma cells Source: International Congress 2019 – Pleural disease: applying the evidence Year: 2019